(Reuters) - Roche might be better off dropping its $6.80 billion bid for genomics specialist Illumina and coming back a year later, as its legacy of paying up after protracted takeovers has damaged its bargaining power, some bankers believe.
(Reuters) - Roche might be better off dropping its $6.80 billion bid for genomics specialist Illumina and coming back a year later, as its legacy of paying up after protracted takeovers has damaged its bargaining power, some bankers believe.
